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1991-7902/Copyrightª 2014, AssociatioAbstract Background/purpose: Bisphosphonates (BPs) are synthetic drugs with antitumor
and bone antiresorptive activities. The use of BPs is suspected to favor the emergence of os-
teonecrosis of the jaw (ONJ), a putative side effect whose pathogenesis remains unclear. Thus,
we aimed to get insights about the impact of BPs on osteoblasts functions, using a three-
dimensional (3D) culture model, which is suggested to be more similar to the in vivo tissues
than monolayers.
Materials and methods: Effects of low (0.1 mM) and high (10 mM) concentrations of zoledronic
acid were investigated on osteoblasts (hFOB 1.19), cultured as multicellular spheroids (MCS).
Proliferation, apoptosis, spheroid growth kinetics, and morphology were studied using the 3-
(4,5-dimethyl-thiazoyl-2yl) 2,5-diphenyl-tetrazolium bromide (MTT) and acid phosphatase
(APH) assays, caspase 3 Western-blotting, phase contrast imaging and scanning electron micro-
scopy (SEM).
Results: Proliferation, apoptosis, and spheroid morphology showed that 10 mM zoledronic acid
(ZA) induced a significant reduction in the relative viable cell number, correlated with morpho-
logical alterations of spheroids, and induction of apoptosis. A lower ZA concentration (0.1 mM)
promoted cell proliferation without affecting growth kinetics or spheroid morphology.
Conclusion: ZA sensitivity of osteoblasts depends on concentration and experimental models.
The dual dose-dependent effects of ZA on osteoblasts cultured as spheroids, thereby promot-
ing or inhibiting cell proliferation, may provide opportunities in tissue engineering. At last, the
hFOB spheroid culture system represents a valuable model for the exploration of the molecularde Biomate´riaux en Site Osseux, Faculte´ d’Odontologie, Universite´ de Rennes 1, 2 Avenue du Pr. Le´on
.
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Bisphosphonates (BPs) are synthetic compounds, both
metabolically stable and structurally similar to inorganic
pyrophosphate. They bind strongly to hydroxyapatite crys-
tals and inhibit bone resorption by reducing physicochem-
ical bone mineral dissolution and decreasing osteoclast
activity. Due to their antiresorptive properties, these drugs
are widely used in the clinical treatment of bone diseases
with increased bone resorption, such as postmenopausal
osteoporosis, Paget’s disease, or lytic bone metastasis.1 BPs
can be divided into two groups depending on their molec-
ular mechanism of action at the cellular level.2 Simple BPs,
such as clodronate and etidronate, are metabolized intra-
cellularly to nonhydrolyzable analogues of ATP. The accu-
mulation of these metabolites in the cytosol of osteoclasts
induces cell death, probably by inhibiting ATP-dependent
intracellular enzymes.3,4 The more potent amino-BPs
[e.g., zoledronic acid (ZA), alendronate, and ibandro-
nate], which are not metabolized, alter osteoclast function
by inhibiting enzymes of the mevalonate biosynthetic
pathway, notably the farnesyl diphosphate synthase (FPPS).
Inhibition of FPPS leads to depletion of the metabolites FPP
and geranylgeranyl diphosphate, necessary for the post-
translational modification (prenylation) of small GTPases,
thereby affecting subcellular localization and function of
these signaling proteins essential for osteoclast survival and
activity.5
The use of BPs has been linked to osteonecrosis of the
jaw (ONJ), particularly in patients after intravenous ther-
apy in the setting of malignancy. BPs-related ONJ (BRONJ)
can be caused by oral trauma or dental extraction, but it
can also occur spontaneously.6,7 Although causality be-
tween BPs exposure and ONJ is still controversial, a clinical
staging system of BRONJ has been developed to more
appropriately diagnose and clinically manage patients,
ranging from Stage 0 (no clinical evidence of necrotic bone,
but nonspecific clinical findings and symptoms) to Stage 3
(exposed necrotic bone with pain, infection, pathologic
fracture, extra oral fistula, oral antral/oral nasal commu-
nication, etc.).8 Various hypotheses have been put forward
to explain BRONJ pathophysiology, which is likely to be
multifactorial. It is postulated that BRONJ localizes on the
jaws because of the heavy bone turnover in this area,
causing BPs to accumulate preferentially in jaws at cyto-
toxic concentrations. Pathophysiology may also involve
suppression of bone turnover and angiogenesis, altered
function of oral mucosal cells, microbial flora, antiin-
flammatory effects, and genetic predispositions.9 Beyond
well-described direct effects of BPs on osteoclastic activity,
significant clinical and experimental evidence indicates
that BPs also influence osteoblast functions.10,11 In vitroand in vivo studies demonstrated dose-dependent effects
of BPs on cell proliferation, cell differentiation, apoptosis,
and matrix mineralization. High concentrations (>10 mM)
generally produce adverse effects on these processes that
may account for the occurrence of BRONJ.12e17 Lower BP
concentrations act positively on osteoblastic function by
promoting survival, proliferation, and differentiation of
bone-forming cells.17e20 While this dual effect of BPs on
osteoblasts is now well established, uncertainty remains
concerning the threshold of cytotoxic and clinically rele-
vant concentrations of BPs, probably because of multiple
experimental models used for investigations.
The objective of this in vitro study was to evaluate the
effects of ZA  a commonly prescribed amino-BP e on os-
teoblasts in a three-dimensional (3D) culture system,
namely multicellular spheroids (MCS).21 The MCS model is
based on the cell’s propensity to self-aggregate when
cultured in nonadhesive conditions. By restoring cell-cell
and cell-matrix interactions, this 3D system more closely
mimics living tissue than monolayer cultures do,22,23 making
MCS-based assays more predictive of in vivo response to
drugs. By examination of cell proliferation, cellular
apoptosis, and spheroid morphology after ZA treatment, we
demonstrated that the dual dose-dependent effect of ZA
already observed in monolayer cultures is conserved in
these osteoblastic microtissue-like cultures.
Materials and methods
Cell culture
The human fetal osteoblast cell line hFOB 1.19 (hFOB) was
purchased from ATCC. hFOB cells were maintained in a 1:1
mixture of phenol red-free Dulbecco’s Modified Eagle’s
medium/Ham’s F-12 medium, supplemented with 10% fetal
bovine serum, 100 IU/mL penicillin, 100 mg/mL strepto-
mycin, 20 mM N-2-hydroxyethylpiperazine-N-2-ethane sul-
fonic acid buffer, 2 mM L-glutamine, and 300 mg/mL G418.
For cell expansion, hFOB cells were incubated at 33.5C and
5% CO2 and fed twice a week. On reaching 80% confluency,
they were passaged using 0.05% trypsin-0.02% Ethyl-
enediaminetetraacetic acid.
Generation and culture of MCS
Formation of hFOB spheroids was achieved using agarose-
coated 96-well tissue culture plates (50 mL of 1.5% agarose
in phosphate-buffered saline (PBS). The seeding density
was 2  103 cells/well. After 96 hours of incubation,
spheroid cultures were treated by replacing 50% (Z 100 mL)
of supernatant with normal medium or medium
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USA) diluted in PBS at 2  final concentration. Half of the
supernatant was replaced every 2 or 3 days with drug-free
or drug-supplemented medium to ensure constant culture
conditions. hFOB MCS were incubated at 33.5C for all
experiments.3-(4,5-dimethyl-thiazoyl-2yl) 2,5-diphenyl-
tetrazolium bromide assay
The relative growth of hFOB cells in monolayer was evalu-
ated using the 3-(4,5-Dimethyl-thiazoyl-2yl) 2,5-diphenyl-
tetrazolium bromide (MTT) assay as previously described.24
Briefly, hFOB cells were seeded in 96-well tissue culture
plates in 200 mL medium/well. After 24 hours, the cells
were incubated with different ZA concentrations for 3 and
10 days. hFOB cells were then exposed to MTT (1 mg/mL)
for 3 hours at 37C. After complete solubilization of for-
mazan crystals in Dimethyl sulfoxide, optical density was
measured on an enzyme-linked immunosorbent assay plate
reader at 570 nm.Acid phosphatase assay
The relative cell proliferation of hFOB in 3D culture was
evaluated after 3 days and 10 days in the absence or
presence of 0.1 or 10 mM ZA using the acid phosphatase
(APH) assay as previously described.25 Briefly, 10 spheroids
from the same culture conditions were pooled, washed with
PBS and transferred into a well of a 96-well microplate. The
supernatant was discarded to a final volume of 100 mL.
Then, 100 mL of the assay buffer (Immunopure p-nitro-
phenyl phosphate 20 mg/10 mL, sodium acetate 0.1 M,
Triton X-100, 0.1%) was added to each well, and plates were
incubated at 37C for 90 minutes. Following incubation,
10 mL of 1 N NaOH was supplemented to each well, and
absorption at 405 nm was measured on an ELISA plate
reader.Microscopy analyses
Phase-contrast imaging of hFOB MCS was performed using
an inverted microscope. Spheroids were assessed visually
for differences in cell morphology from Day 0 (i.e., 96 hours
after spheroid initiation) to Day 14, in the absence or
presence of ZA. At least 48 MCS from each indicated time
point were used to calculate the average diameter using
Photoshop software (Adobe Systems France SAS112 avenue
Kle´ber, 75784 Paris Cedex 16). In addition, hFOB MCS
cultivated for 3 days or 10 days in drug-free or drug-
supplemented medium were examined by scanning elec-
tron microscopy (SEM). Spheroids were rinsed twice in PBS
and fixed for 3 hours with 2.5% glutaraldehyde in PBS. Then,
samples were washed twice in PBS and dehydrated in
graded alcohol (80, 95, and 100) and acetone. After
critical drying point (CPD 010, Balzers Union, Balzers,
Lichtenstein, Germany) using liquid carbon dioxide, sam-
ples were coated with a thin layer of goldepalladium and
observed via SEM.Protein extraction and Western blot analysis
After 3 or 10 days of ZA treatment, hFOB MCS were
collected, rinsed twice in cold PBS and homogenized in cold
Radioimmunoprecipitation assay (buffer) protein extraction
buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.5%
Na-deoxycholate, 0.1% sodium dodecyl sulfate, 2 mM
EDTA). Homogenates were then sonicated, incubated on ice
for 30 minutes and centrifuged at 14,000g for 15 minutes at
4C. Supernatants (total protein) and pellets (cellular
debris) were collected and stored at 80C until use. Pro-
teins were quantified with the Micro BCA Protein Assay Kit
(Thermo Scientific, Waltham, MA, USA), according to the
manufacturer’s instructions. An amount of 20 mg of total
proteins were separated by electrophoresis in a 10% poly-
acrylamide SDS gel and transferred onto a Polyvinylidene
fluoride membrane (Millipore, Merck KGaA, Darmstadt,
Germany). After saturation, membranes were incubated
with rabbit monoclonal antibodies raised against cleaved
caspase-3 or alpha-tubulin. HRP-conjugated secondary an-
tibodies were used subsequently before enhanced chemi-
luminescent signal detection. All antibodies were
purchased from Cell Signaling Technology (Ozyme, 10
Avenue Ampe`re, CS 30268, 78053 St Quentin en Yvelines
Cedex).
Statistical analysis
The data are expressed as means  standard deviation (SD).
All experiments were conducted in triplicate. Comparisons
across multiple experimental groups were performed using
a one-way analysis of variance (ANOVA) followed by the
protected least significant difference Fisher test using
StatView v5.0 software (SAS France, Domaine de Gre´gy,
Gre´gy-sur-Yerres, 77257 Brie Comte Robert Cedex). The
observed differences relative to a probability of P < 0.05
were considered significant.Results
Effect of ZA on hFOB cell proliferation in monolayer
and 3D cultures
To test whether the culture model influences ZA sensitivity
of hFOB cells, a comparative study of relative cell growth
between monolayer and spheroid cultures was carried out.
Analysis of cell proliferation in hFOB monolayer culture
was realized using MTT assay after 3 days or 10 days culture
with different ZA concentrations (Fig. 1). Results are
documented relative to the respective untreated control
(set to 100%). Exposure of hFOB to 0.1 mM ZA did not alter
cell proliferation when compared with control cells
(101.7%  7.2% at Day 3, 102.5%  5.5% at Day 10). In
contrast, relative growth of hFOB cells in monolayer culture
was significantly decreased after 3 days and 10 days in
presence of 10 mM ZA, respectively, to 87.4%  7.4%
(P < 0.0001) and 40.4%  9.7% (P < 0.0001) of untreated
cells’ growth.
To explore the sensitivity of hFOB cells to ZA treatment
in 3D cultures, the relative number of viable cells in hFOB
Figure 3 Monitoring of hFOB multicellular spheroids (MCS)
growth. Graph visualizes spheroid diameter evolution kinetics
of hFOB MCS grown in absence of zoledronic acid (ZA) (,) or
incubated with 0.1 mM (D) or 10 mM (C) ZA for up to 14 days.
Data points are mean diameter  standard deviation (SD) from
48 individual spheroids (**P < 0.0001 compared to control).
Figure 1 Relative cell growth of hFOB cells in two-
dimensional (2-D) culture. Relative growth of hFOB cells in
monolayer culture was determined using a 3-(4,5-dimethyl-
thiazoyl-2yl) 2,5-diphenyl-tetrazolium bromide (MTT) assay
after 3 days (D3) or 10 days (D10) of treatment with indicated
concentrations of zoledronic acid (ZA). Number of viable cells
is presented as percent of phosphate-buffered saline (PBS)-
treated control spheroids (Ctrl), expressed as mean  standard
deviation (SD) of triplicate experiments (**P < 0.0001
compared to control).
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was determined using the APH assay (Fig. 2) in comparison
with respective untreated controls (set to 100%). No sig-
nificant difference was found between experimental con-
ditions at Day 3 (104.3%  9.9% for 0.1 mM, 94.2%  8.4% for
10 mM), whereas a lower relative viable cell number was
observed after 10 days incubation in 10 mM ZA
(80.4%  12.3%; P < 0.0001), in agreement with MTT assay
results, although growth inhibition appeared much more
pronounced in monolayer cultures. By contrast, 10 daysFigure 2 Relative cell growth of hFOB cells in three-
dimensional (3D) culture. Relative cell growth in hFOB multi-
cellular spheroids (MCS) was determined using an acid phos-
phatase (APH) assay following 3 days (D3) or 10 days (D10) of
treatment with indicated concentrations of zoledronic acid
(ZA). Results are presented as percent of APH activity in
phosphate-buffered saline (PBS)-treated control spheroids
(Ctrl), expressed as mean  standard deviation (SD) of tripli-
cate experiments (**P < 0.0001 compared to control).treatment with 0.1 mM ZA seemed to slightly promote hFOB
cell proliferation (114.5%  9.0%; P < 0.0001) only when
cultured as MCS.Impact of ZA on hFOB MCS growth and morphology
Monitoring of ZA effects on hFOB MCS growth and
morphology was achieved through a combination of phase-
contrast imaging and SEM analysis. Spheroid growth kinetics
as determined through MCS diameter measurements (Figs.
3 and 4) revealed a very gradual and linear increase of
mean spheroid size when cultured in the absence of ZA,
from 280 mm on Day 0 to 405 mm on Day 14. A nearly
identical growth curve was obtained with spheroids incu-
bated with 0.1 mM ZA, without any statistically significant
difference in spheroid size at any time point. Growth in-
hibition was evident for hFOB MCS treated with 10 mM ZA.
Indeed, the diameter increase was almost totally abrogated
as soon as 3 days culture, the difference in diameter being
highly significant at Day 7 (P < 0.0001) when compared with
untreated MCS. Interestingly, spheroid size reached a sta-
ble plateau (around 290 mm) maintained for at least 14 days
of culture. To test whether ZA-induced growth inhibition of
hFOB spheroid was correlated with morphological alter-
ations, SEM analysis was carried out at 3 days or 10 days
culture in drug-free or drug-supplemented medium (Fig. 5).
Microscopic examination of untreated spheroids after 3 or
10 days showed a compact spherical architecture without
any distinguishable osteoblast  except for the round-
shaped detaching ones  indicating an extremely dense
cellular network. At high magnification (3000) the surface
of the MCS displayed filamentous structures, suggestive of
cell membrane protrusions. SEM micrographs of spheroids
treated with 0.1 mM ZA for 3 or 10 days, or with 10 mM ZA for
3 days did not reveal any morphological difference with
control spheroids. In contrast, the structural integrity of
hFOB MCS incubated for 10 days with 10 mM ZA appeared
dramatically affected. Indeed, although spheroids
conserved a spherical aspect, they were characterized by a
highly irregular and grainy surface.
Figure 4 Phase-contrast imaging of hFOB multicellular spheroids (MCS). Representative phase-contrast images of hFOB MCS are
shown, illustrating the inhibitory effect of 10 mM zoledronic acid (ZA) on spheroid growth. Scale bar, 100 mm.
Figure 5 Examination of hFOB multicellular spheroids (MCS) structural integrity by scanning electron microscopy (SEM). SEM
micrographs of hFOB MCS incubated for 3 days (A, D, G) or 10 days (B, C, E, F, H, I) in the absence or presence of indicated
zoledronic acid (ZA) concentrations are shown. C, F and I correspond to high-magnification (3000) images of insets in B, E and H,
respectively. Scale bars, 10 mm.
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Figure 6 Western blot analysis of cleaved caspase-3 in hFOB
multicellular spheroids (MCS) upon treatment with zoledronic
acid (ZA). Protein level of the active form of caspase-3 was
investigated in control spheroids or spheroids exposed to 0.1 or
10 mM ZA during 3 or 10 days. Tubulin was used as a loading
control.
Zoledronic acid effects on 3D-cultured osteoblasts 13Immunodetection of the active form of caspase-3
during ZA treatment
Because exposure to the highest concentration of ZA
compromised hFOB growth kinetics and morphology, we
further examined whether the caspase cascade was trig-
gered in response to ZA by performing Western blot analysis
of cleaved caspase-3 (Fig. 6). Immunodetection on total
protein extracts from treated and untreated hFOB MCS
revealed the presence of the active form of caspase-3 after
3 days incubation with 10 mM ZA. Moreover, no electro-
phoretic band was detected at Day 10, indicating a tran-
sient activation of the apoptotic cascade.Discussion
While BPs are widely used in clinical practice for their bone
antiresorptive action, accumulating evidence demonstrates
that osteoclasts are not the only direct cellular targets of
BPs and that these drugs also affect the activity of bone-
forming osteoblastic cells. The findings that BPs modulate
expression of receptor activator of NF-kappaB ligand
(RANKL) and osteoprotegerin in osteoblasts that may in turn
indirectly interfere with differentiation and survival of os-
teoclasts highlight the complexity of BPs action on bone
cells.26,27 In this context, the clinical study of Recker and
colleagues, showing an increase of the mineral apposition
rate in patients intravenously treated with ZA, exemplifies
the current view that BPs modulate both arms of bone
remodeling.28 However, the molecular mechanisms by
which BPs regulate the activity of osteoblasts is not
completely understood.
As seen above, literature data indicate that high
(micromolar) concentrations of BPs compromise viability
and function of osteoblastic cells, whereas lower concen-
trations stimulate osteoblast proliferation/differentiation
and inhibit osteoblast/osteocyte apoptosis. In line with
these observations, we demonstrated that ZA treatment of
hFOB MCS induces positive or negative effects on osteo-
blasts in a dose-dependent manner. The highest concen-
tration (10 mM) blocks cell proliferation, alters MCS
morphology, and induces apoptosis that might be partly
responsible for the development of BRONJ, whereas the
lowest concentration (0.1 mM) promotes slight but signifi-
cant cell growth.Our findings that 10 mM ZA inhibits the increase of MCS
diameter after 3 days of incubation, and that the size of
MCS remains constant the following days, suggest that ZA
exerts a cytostatic effect on osteoblasts, as already shown
in other cell types.29,30 The transient activation of caspase
cascade may signify that ZA has a pro-apoptotic effect as
well, but only on some sensitive cells. To test whether ZA-
induced growth inhibition was correlated with induction of
bone-forming activities, von Kossa staining was performed
but did not reveal any mineralized nodules (data not
shown). We conclude that the nonproliferative state of
hFOB cells is not associated with the differentiation pro-
cess, in contrast with previous results obtained with hFOB
monolayer cultures.17,31 Further supporting the idea that
3D MCS model presents specific properties conditioning the
effect of ZA on osteoblastic cells, our results from MTT and
APH assays showed that the antiproliferative effect of a
high concentration of ZA is much more acute in monolayers
than in MCS, suggesting a protective effect of the 3D
experimental condition. Emergence of a hypoxia-related
mechanism of resistance inside the MCS may provide an
explanation for this phenomenon, hypoxic conditions pre-
venting the antiproliferative and pro-apoptotic effects of
amino-BPs on osteoblast-like cells.32 Alternatively, limited
penetration and diffusion of ZA within the MCS may confine
the pharmacological action of ZA to the cells located in the
outermost layer of the spheroid, consequently reducing the
proportion of cells exposed to ZA in comparison with
monolayer cultures. Further studies would greatly benefit
from fluorescently labeled conjugates of amino-BPs, which
may provide useful information on the gradient distribution
of these drugs within MCS, as well as on the mechanisms of
cellular uptake and potential transcytosis.33,34 Conversely,
we have described that 0.1 mM ZA moderately promotes
cell growth of MCS. This anabolic effect on osteoblasts has
been demonstrated for other amino-BPs and is thought to
involve binding to and inhibition of protein tyrosine phos-
phatases.35 However, why this proliferative effect is
restricted to hFOB cells cultured as MCS remains to be
solved.
Our observation that the biological response to ZA not
only depends on the concentration but also on the experi-
mental model, as already proposed,36 emphasizes the great
potential of the MCS model as a microtissue-like model for
drug evaluation.37 Indeed, the restoration of cell-cell and
cell-matrix interactions confers to the MCS model structural
and functional properties physiologically more relevant
than monolayer cultures, giving to MCS-based assays a
better predictive value of in vivo drug efficacy. For these
reasons, in cancer research, the MCS represents an
incomparable system for drug screening and metastasis
analysis, as an avascular tumor model reproducing the
in vivo pathophysiology of tumor tissue.37,38
Also, the MCS constitutes a highly valuable research tool
for tissue engineering with multiple applications in regen-
erative medicine. For example, Kelm and colleagues
generated vascularized macrotissues by assembling indi-
vidual MCS coated with endothelial cells, and observed that
these macrotissues were connected to the host’s vascular
system after in vivo implantation, illustrating the promising
potential of heterotypic MCS as minimal building blocks for
ex vivo generation of macrotissues.39
14 F. Thibaut et alConcerning the specific field of bone tissue engineering,
multiple therapeutic strategies based on direct (coating,
incorporation) or indirect (adjunct therapy) association of
BPs with scaffolds (bioactive glasses, hydroxyapatite scaf-
folds, implants) have been developed.40 These applications
rely on the mechanical and putative osteoconductive and
osteoinductive properties of bone substitutes, in conjunc-
tion with the local or systemic delivery of BPs, to promote
bone regeneration. In this context, the hFOB spheroid
culture system represents a convenient in vitro model for
studying the effects of BPs on osteoblasts, and may greatly
contribute to our understanding of their mechanisms of
action on bone cells in the context of both tissue-
engineered bone regeneration and physiopathology of
BRONJ.
Based on the hFOB MCS model, this study shows that ZA
exerts dual dose-dependent effects on osteoblast functions
in 3D cultures, inducing MCS growth arrest and apoptosis at
micromolar concentrations, but promoting cell prolifera-
tion at a lower level. In addition to constituting a model of
choice for elucidating the mechanisms of action of BPs on
osteoblasts, the hFOB MCS culture system may also be very
useful in assessing the effects of new bone substitutes on
bone-forming cells and, more generally, in screening po-
tential therapeutic molecules. Nevertheless, further
studies are needed to improve the physiological relevance
of the MCS model, for example through the development of
heterotypic spheroids mixing osteoblasts and endothelial
cells. Such experimental models may not only contribute to
in vitro molecular and cellular studies, but also have great
applications in tissue engineering, especially as building
blocks for tissue reconstruction with autologous cells.
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